4,901 trials
End Stage Renal Disease · Renal Impairment
Primary: Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to Infinity (AUC0-inf) — 17100; 21100; 18500 ng•hr/mL
Lymphoma, B-Cell
Primary: Objective Response Rate (ORR) Using International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma as Assessed by Independent Central Review — 42.9…
Acute Myelogenous Leukemia · Acute Lymphocytic Leukemia · Myelodysplastic Syndromes
Primary: Number of Participants With Graft Failure (Pilot Study Only) — 0 Participants
Atropine Bioequivalence
Primary: The Bioequivalence of Atropine Sulfate Administered SL Versus Administered IM as Measured by Area Under the Analyte Concentration Versus Time Curve to Infinity (AUCinf)…
Cerebral Palsy
Primary: Change in Preferred Walking Speed — 0.09; 0.13 m/s
Renal Impairment
Primary: Maximum Serum Concentration (Cmax) of HM15912 — 2811.25; 3000.00 ng/mL
Ebola
Primary: Safety and Tolerability of ChAdOx1 biEBOV in Healthy Volunteers: Number of Participants With Occurrence of Solicited Local and Systemic Reactogenicity Signs and Symptoms…
Safety · Bioavailability · Pharmacokinetics
Primary: Relative Bioavailability of Linaprazan Comparing Test Formulation vs. Reference Formulation of Linaprazan Glurate. Ratios of AUCinf and AUClast — 12341; 25001; 10016.2…
Healthy
Primary: Number of Subjects With On-treatment Drug-related Adverse Events (AEs). — 0; 1; 4; 4 Participants
Healthy Volunteers
Primary: Comparison of the Pharmacokinetic (PK) Profiles Between MB05 and EU-Synagis®, Between MB05 and US-Synagis® and Between EU-Synagis® and US-Synagis® in Terms of Area Under…
HIV Infections
Primary: Part 1: Number of Participants With Adverse Events (AEs) — 3; 2; 1; 3 Participants
Healthy
Primary: Part 1: Area Under the Concentration-time Curve of BI 1358894 Over the Time Interval From 0 to Infinity After i.v. Administration and After Oral Administration…
Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2 (Disorder)
Primary: Number of Participants With Treatment-emergent Adverse Events as Assessed by Protocol Definition of AE — 3; 0; 0; 1 Participants
Healthy
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab in a Citrate-free Solution Formulation Compared to the Solution Formulation — 20.9; 20.9 micrograms…
Human Immunodeficiency Virus I Infection · Immunodeficiency Virus Type 1, Human · Human Immunodeficiency Virus Type 1
Primary: Number and Types of Adverse Events (AEs), Including Serious Adverse Events (SAEs), and AEs Leading to Treatment Discontinuation in Participants Receiving MGD020 Alone in…